Income statement
ILS
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 38M | 0 | 328K | 0 | 0 |
| Gross Profit | 11M | 0 | 328K | 0 | 0 |
| Operating Income | -3M | -3M | -9M | -2M | -3M |
| EBITDA | -3M | 0 | 0 | 0 | -22M |
| Net Income | -5M | -5M | -18M | -2M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.05
+0.00% today
1Y Change
-97.51%
Window
Jun 27, 2025 → Jun 25, 2026
Coverage: 248 bars · Jun 27, 2025 → Jun 25, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Elbit Imaging Ltd. (EMITF) is a Healthcare stock with a market cap of $80.00M and listed on OTC. The stock last traded around $0.05 and down 97.5% across the available one-year price window (Jun 27, 2025 → Jun 25, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +24.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +24.0%, free cash flow -1138.7% with operating margin 0.0% and ROIC -3.6%. Stock Foundry combines EMITF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EMITF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EMITF Max Drawdown
-97.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for EMITF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$20.5M
-770.4% YoY
Free Cash Flow
-$3.4M
+1.7% YoY
Revenue Growth
+0.0%
EPS Growth
+24.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
ILS
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 38M | 0 | 328K | 0 | 0 |
| Gross Profit | 11M | 0 | 328K | 0 | 0 |
| Operating Income | -3M | -3M | -9M | -2M | -3M |
| EBITDA | -3M | 0 | 0 | 0 | -22M |
| Net Income | -5M | -5M | -18M | -2M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
ILS
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33M | 40M | 38M | 28M | 17M |
| Total Assets | 380M | 72M | 64M | 64M | 72M |
| Total Liabilities | 293M | 4M | 1M | 1M | 1M |
| Shareholder Equity | 78M | 68M | 63M | 63M | 71M |
| Total Debt | 232M | 2M | 2M | 0 | 0 |
| Net Debt | 198M | -38M | 2M | -28M | -17M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+1.7% YoY
Capital Expenditures
0
Free Cash Flow
3M
+1.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-8.1%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.